title: Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure.
abstract: We tested the efficacy of three selective agonists of prostaglandin E(2) (PGE(2)) receptor, EP2 (CP-536,745-01), EP2/4 (CP-043,305-02), and EP4 (CP-044,519-02), in two models of acute and chronic kidney failure. In the nephrotoxic mercury chloride (HgCl(2)) rat model of acute kidney failure systemically administered EP4 agonist reduced the serum creatinine values and increased the survival rate. Although the EP2 or the EP2/4 agonist did not change the serum creatinine values, the EP2 receptor agonist increased the survival rate. Histological evaluation of kidneys from EP4-treated rats indicated less proximal tubular necrosis and less apoptotic cells. In a rat model of chronic renal failure, the three receptor agonists decreased the serum creatinine and increased the glomerular filtration rate at 9 weeks following therapy. Kidneys treated with the EP4 agonist had less glomerular sclerosis, better preservation of proximal and distal tubules and blood vessels, increased convoluted epithelium proliferation and less apoptotic cells. Nephrectomy had no influence on the expression of the EP4 receptor, whereas EP2 receptor expression was reduced by 50% and then corrected following treatment with EP2 and EP2/4 receptor agonists. These findings suggest that PGE(2) has an important role in acute kidney failure via the EP4 receptor, whereas in chronic kidney failure both EP2 and EP4 receptors are equally important in preserving the progression of chronic kidney failure. Thus, agonism of EP2 and EP4 receptors may provide a basis for treating acute and chronic kidney failure.
authors.affiliation: Laboratory of Mineralized Tissues, Department of Anatomy, Zagreb Medical School, University of Zagreb, Zagreb, Croatia. vukicev@mef.hr
authors.forename: S
authors.initials: S
authors.lastname: Vukicevic
authors.forename: P
authors.initials: P
authors.lastname: Simic
authors.forename: F
authors.initials: F
authors.lastname: Borovecki
authors.forename: L
authors.initials: L
authors.lastname: Grgurevic
authors.forename: D
authors.initials: D
authors.lastname: Rogic
authors.forename: I
authors.initials: I
authors.lastname: Orlic
authors.forename: W A
authors.initials: WA
authors.lastname: Grasser
authors.forename: D D
authors.initials: DD
authors.lastname: Thompson
authors.forename: V M
authors.initials: VM
authors.lastname: Paralkar
mesh_terms: D058186:Acute Kidney Injury / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D015232:Dinoprostone / Q000378:metabolism*; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D008627:Mercuric Chloride / Q000633:toxicity; D009392:Nephrectomy; D051381:Rats; D017208:Rats, Wistar; D018078:Receptors, Prostaglandin E / Q000819:agonists* / Q000502:physiology*; D058307:Receptors, Prostaglandin E, EP2 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype
chemical_list: C545646:Ptger2 protein, rat; C545652:Ptger4 protein, rat; D018078:Receptors, Prostaglandin E; D058307:Receptors, Prostaglandin E, EP2 Subtype; D058309:Receptors, Prostaglandin E, EP4 Subtype; D008627:Mercuric Chloride; D015232:Dinoprostone